 Carolyn Lefkowits
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 20 | 2023 | 70 | 7.380 |
Why?
| | Cancer Pain | 6 | 2019 | 20 | 3.050 |
Why?
| | Palliative Care | 15 | 2023 | 641 | 3.010 |
Why?
| | Analgesics, Opioid | 7 | 2021 | 771 | 2.160 |
Why?
| | Pain Management | 5 | 2021 | 285 | 1.740 |
Why?
| | Medical Oncology | 8 | 2022 | 229 | 1.550 |
Why?
| | Surgical Oncology | 3 | 2019 | 18 | 1.430 |
Why?
| | Gynecology | 7 | 2020 | 163 | 1.360 |
Why?
| | Hot Flashes | 3 | 2013 | 72 | 1.200 |
Why?
| | Pain, Postoperative | 3 | 2021 | 190 | 0.900 |
Why?
| | Referral and Consultation | 4 | 2017 | 632 | 0.840 |
Why?
| | Hospice Care | 2 | 2023 | 184 | 0.840 |
Why?
| | Terminal Care | 3 | 2023 | 212 | 0.830 |
Why?
| | Opioid-Related Disorders | 5 | 2019 | 413 | 0.760 |
Why?
| | Communication | 3 | 2020 | 734 | 0.650 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1381 | 0.590 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 970 | 0.570 |
Why?
| | Neoplasms | 2 | 2021 | 2086 | 0.540 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 213 | 0.540 |
Why?
| | Perinatal Care | 1 | 2016 | 36 | 0.540 |
Why?
| | Palliative Medicine | 1 | 2014 | 14 | 0.470 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 2014 | 3 | 0.460 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 15 | 0.450 |
Why?
| | Ambulatory Care | 2 | 2017 | 479 | 0.450 |
Why?
| | Female | 30 | 2023 | 59324 | 0.450 |
Why?
| | Endometrial Neoplasms | 3 | 2020 | 141 | 0.440 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2013 | 22 | 0.410 |
Why?
| | Cost of Illness | 1 | 2014 | 254 | 0.410 |
Why?
| | Amines | 1 | 2013 | 34 | 0.410 |
Why?
| | Needs Assessment | 1 | 2014 | 315 | 0.400 |
Why?
| | Oncologists | 3 | 2022 | 30 | 0.400 |
Why?
| | Complementary Therapies | 1 | 2013 | 74 | 0.390 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 144 | 0.390 |
Why?
| | Analgesics | 1 | 2013 | 156 | 0.370 |
Why?
| | Quality of Life | 6 | 2023 | 2343 | 0.370 |
Why?
| | Humans | 33 | 2023 | 114045 | 0.360 |
Why?
| | Health Services Accessibility | 1 | 2016 | 756 | 0.360 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 366 | 0.350 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2022 | 69 | 0.340 |
Why?
| | Middle Aged | 16 | 2021 | 26605 | 0.340 |
Why?
| | Guideline Adherence | 1 | 2014 | 489 | 0.340 |
Why?
| | Employment | 2 | 2021 | 137 | 0.340 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 913 | 0.320 |
Why?
| | Aged | 12 | 2020 | 18969 | 0.310 |
Why?
| | Epidemics | 2 | 2018 | 66 | 0.280 |
Why?
| | Advance Care Planning | 2 | 2020 | 195 | 0.250 |
Why?
| | Breast Neoplasms | 2 | 2013 | 1846 | 0.240 |
Why?
| | Adult | 11 | 2021 | 30375 | 0.240 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6306 | 0.230 |
Why?
| | Medical Futility | 1 | 2023 | 20 | 0.220 |
Why?
| | Patient Care Team | 2 | 2019 | 517 | 0.220 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 44 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 850 | 0.200 |
Why?
| | Retrospective Studies | 7 | 2022 | 12521 | 0.200 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2013 | 138 | 0.190 |
Why?
| | Cohort Studies | 4 | 2021 | 4883 | 0.190 |
Why?
| | Brachytherapy | 2 | 2019 | 100 | 0.180 |
Why?
| | Ethics, Medical | 1 | 2020 | 69 | 0.170 |
Why?
| | Enoxaparin | 1 | 2020 | 52 | 0.170 |
Why?
| | Radiosurgery | 1 | 2022 | 299 | 0.170 |
Why?
| | Young Adult | 5 | 2020 | 10444 | 0.160 |
Why?
| | Pyridones | 1 | 2020 | 122 | 0.160 |
Why?
| | Infection Control | 1 | 2020 | 132 | 0.160 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 46 | 0.160 |
Why?
| | Hospices | 1 | 2020 | 83 | 0.160 |
Why?
| | Carcinosarcoma | 1 | 2018 | 17 | 0.150 |
Why?
| | Postoperative Care | 1 | 2020 | 223 | 0.150 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 73 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2019 | 618 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2019 | 237 | 0.140 |
Why?
| | Preoperative Care | 1 | 2019 | 319 | 0.140 |
Why?
| | beta Catenin | 1 | 2019 | 218 | 0.140 |
Why?
| | Pyrazoles | 1 | 2020 | 361 | 0.140 |
Why?
| | Databases, Factual | 2 | 2019 | 1125 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2017 | 29 | 0.140 |
Why?
| | Cancer Survivors | 1 | 2020 | 205 | 0.140 |
Why?
| | Perinatal Death | 1 | 2016 | 22 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 230 | 0.140 |
Why?
| | Survival Analysis | 1 | 2020 | 1206 | 0.140 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 29 | 0.140 |
Why?
| | Truth Disclosure | 1 | 2016 | 39 | 0.130 |
Why?
| | Life Expectancy | 1 | 2016 | 46 | 0.130 |
Why?
| | Nausea | 1 | 2016 | 99 | 0.130 |
Why?
| | Anticoagulants | 1 | 2020 | 547 | 0.130 |
Why?
| | Mood Disorders | 1 | 2016 | 112 | 0.130 |
Why?
| | Self Efficacy | 1 | 2019 | 353 | 0.130 |
Why?
| | Hospitalization | 2 | 2014 | 1762 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 334 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 326 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2022 | 966 | 0.120 |
Why?
| | Outpatients | 2 | 2017 | 325 | 0.120 |
Why?
| | Program Evaluation | 1 | 2019 | 820 | 0.120 |
Why?
| | Physician-Patient Relations | 1 | 2019 | 459 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2019 | 666 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 662 | 0.110 |
Why?
| | Mass Screening | 1 | 2020 | 979 | 0.110 |
Why?
| | Stellate Ganglion | 1 | 2013 | 4 | 0.110 |
Why?
| | Societies, Medical | 1 | 2016 | 655 | 0.110 |
Why?
| | Anxiety | 1 | 2019 | 843 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 22 | 0.100 |
Why?
| | Symptom Assessment | 1 | 2014 | 119 | 0.100 |
Why?
| | Ovariectomy | 1 | 2013 | 116 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1310 | 0.100 |
Why?
| | Nerve Block | 1 | 2013 | 60 | 0.100 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 76 | 0.100 |
Why?
| | Tamoxifen | 1 | 2013 | 190 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 386 | 0.100 |
Why?
| | Fellowships and Scholarships | 1 | 2014 | 224 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 252 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 337 | 0.090 |
Why?
| | Depression | 1 | 2019 | 1133 | 0.090 |
Why?
| | Pain | 1 | 2016 | 701 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 618 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1356 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1422 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4392 | 0.090 |
Why?
| | Adolescent | 4 | 2020 | 17800 | 0.090 |
Why?
| | Colorado | 1 | 2019 | 4090 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2020 | 2122 | 0.080 |
Why?
| | Quality Improvement | 1 | 2016 | 944 | 0.080 |
Why?
| | Logistic Models | 1 | 2014 | 1829 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 187 | 0.080 |
Why?
| | Curriculum | 1 | 2014 | 813 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 182 | 0.070 |
Why?
| | United States | 3 | 2020 | 12137 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4595 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2537 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2016 | 5038 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1162 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 8614 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2021 | 3003 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2022 | 66 | 0.050 |
Why?
| | Unemployment | 1 | 2020 | 39 | 0.040 |
Why?
| | Health Benefit Plans, Employee | 1 | 2020 | 20 | 0.040 |
Why?
| | Resource Allocation | 1 | 2020 | 37 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 62 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 32 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 241 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 140 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 195 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 332 | 0.040 |
Why?
| | Male | 2 | 2013 | 55396 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 247 | 0.040 |
Why?
| | Critical Care | 1 | 2020 | 472 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 445 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 3315 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1204 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1016 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1032 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1791 | 0.030 |
Why?
| | Mutation | 1 | 2019 | 3338 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 2958 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 5499 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 6195 | 0.020 |
Why?
|
|
Lefkowits's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|